Invivyd Completes Patient Enrollment in Phase 3 COVID-19 Trial for VYD2311

Invivyd announced June 16, 2026, it has completed patient enrollment in the Phase 3 LIBERTY trial evaluating VYD2311 as a COVID-19 treatment. The milestone marks the final stage of patient recruitment before the company collects efficacy and safety data for potential regulatory submission. VYD2311 is Invivyd's investigational monoclonal antibody therapy designed to prevent or treat COVID-19 infections. Phase 3 trials are the last step before seeking FDA approval and typically involve larger patient populations to confirm clinical benefit. The completion of enrollment means all participants are now enrolled, though data readout timing was not disclosed in the announcement. The biotechnology company has been developing next-generation antibody therapies targeting evolving SARS-CoV-2 variants. Investors typically monitor enrollment milestones as key indicators of trial progress and potential timelines for commercialization.